Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-79635322 in Relapsed or Refractory Multiple Myeloma
NCT07266441Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Trispecific Antibodies, T-cell Engagers
- Countries
- 8
01
Overview
A Phase 2 trial of ramantamig in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Feb 2026; status: active, not recruiting.
02
Drugs
ramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07266441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266441.